Acclaim for a precision oncology pioneer in Oregon

Like few other drugs in the history of oncology, Gleevec transformed the outlook for patients: a disease with a life expectancy of less than five years – chronic myeloid leukemia – became a...

Cracking the code of advanced prostate cancer

Understanding the tumor-specific alterations that are most important for prostate cancer aggressiveness and treatment decision-making will be the focus of a Marquam Hill...

A new line of attack on deadly prostate cancers

Researchers have uncovered a potential drug target for stopping castration-resistant prostate tumors – the second leading cause of cancer death in the U.S. For decades, drug development for...

How to retarget cancers that have evaded targeted therapy

Targeted therapy drugs transformed the outlook for people with the rare cancers known as gastrointestinal stromal tumors, enabling some to survive a decade or longer. A fraction of GIST patients,...

Breaking through the limits of cancer medicine

Gordon Mills, M.D., Ph.D., the new director of precision oncology at Oregon Health & Science University, outlines a vision for the field. Photo: Gordon Mills, M.D., Ph.D. (OHSU/Kristyna...

Zeroing in on drug combos against a formidable form of leukemia

A heat map by Kurtz et al. comparing the sensitivities of leukemia cells to drug combinations. Darker red indicates drug combinations exhibiting higher efficacy than either agent alone. Targeted...

Riveting survival stories from the early clinical trials of Gleevec

Medicine had never seen anything like it before, Brian Druker, M.D., recalled. "These are people who’d been told to get their affairs in order. And now their blood counts are normal," the...

The cancer drug that “changed everything”

Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments. It transformed the outlook for people diagnosed with chronic myeloid leukemia. A...